Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
imetelstat
- Development stage
- Approved
- Lead developer
- Geron
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Imetelstat, marketed under the brand name Rytelo, is a first-in-class oligonucleotide telomerase inhibitor. It is indicated for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndrome (MDS) who have transfusion-dependent anemia and are unresponsive to or ineligible for erythropoiesis-stimulating agents (ESAs). Administered intravenously, imetelstat functions by binding with high affinity to the template region of the RNA component of human telomerase (hTR), thereby directly and competitively inhibiting telomerase enzymatic activity. This inhibition results in the progressive shortening of telomeres in malignant cells, subsequently reducing their proliferation and inducing apoptotic cell death. The drug exhibits a degree of selectivity for malignant stem and progenitor cells due to their typically higher telomerase activity compared to normal cells. Imetelstat received FDA approval in June 2024 for its MDS indication. It is also currently being investigated for potential use in treating other cancer types.
- Brand names
- Rytelo
- Other names
- imetelstat sodiumGRN163LGRN-163LGRN 163L
02
Targets
TERC (Telomerase RNA component)TERT (Telomerase)
Beyond the preview
Go deeper on imetelstat.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on imetelstat.